Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Arcturus Therapeutics Holdings stock price, quote, forecast and news

ARCT
US03969T1097
A2PMAS

Price

20.55
Today +/-
-0.41
Today %
-2.21 %
P

Arcturus Therapeutics Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Arcturus Therapeutics Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Arcturus Therapeutics Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Arcturus Therapeutics Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Arcturus Therapeutics Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Arcturus Therapeutics Holdings Stock Price History

DateArcturus Therapeutics Holdings Price
9/18/202420.55 undefined
9/17/202421.01 undefined
9/16/202420.61 undefined
9/13/202420.75 undefined
9/12/202419.91 undefined
9/11/202420.98 undefined
9/10/202419.76 undefined
9/9/202419.00 undefined
9/6/202418.69 undefined
9/5/202418.82 undefined
9/4/202419.06 undefined
9/3/202419.39 undefined
8/30/202421.10 undefined
8/29/202420.93 undefined
8/28/202420.84 undefined
8/27/202420.62 undefined
8/26/202421.44 undefined
8/23/202421.99 undefined
8/22/202421.47 undefined
8/21/202421.88 undefined

Arcturus Therapeutics Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Arcturus Therapeutics Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Arcturus Therapeutics Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Arcturus Therapeutics Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Arcturus Therapeutics Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Arcturus Therapeutics Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Arcturus Therapeutics Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Arcturus Therapeutics Holdings’s growth potential.

Arcturus Therapeutics Holdings Revenue, EBIT and net profit per share

DateArcturus Therapeutics Holdings RevenueArcturus Therapeutics Holdings EBITArcturus Therapeutics Holdings Net Income
2029e1.36 B undefined0 undefined506.75 M undefined
2028e1.04 B undefined591.63 M undefined392.66 M undefined
2027e567.75 M undefined194.23 M undefined135.42 M undefined
2026e361.73 M undefined90.42 M undefined19.75 M undefined
2025e199.03 M undefined-45.85 M undefined-59.72 M undefined
2024e189.25 M undefined-95.36 M undefined-83.51 M undefined
2023166.8 M undefined-78.21 M undefined-29.73 M undefined
2022206 M undefined12.2 M undefined9.3 M undefined
202112.4 M undefined-202.9 M undefined-203.7 M undefined
20209.5 M undefined-71.5 M undefined-72.1 M undefined
201920.8 M undefined-25.5 M undefined-26 M undefined
201815.8 M undefined-21.8 M undefined-21.8 M undefined
201713 M undefined-10.5 M undefined-10.9 M undefined
201620.4 M undefined-1 M undefined-1.6 M undefined
20150 undefined-19.7 M undefined-19.4 M undefined
20140 undefined-33.1 M undefined-32.8 M undefined
20130 undefined-10.3 M undefined-10.5 M undefined
20120 undefined-1.5 M undefined-1.6 M undefined
20110 undefined-3.9 M undefined-3.9 M undefined

Arcturus Therapeutics Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000000.020.010.020.020.010.010.210.170.190.20.360.571.041.36
-------35.0015.3833.33-55.0033.331,616.67-19.4213.865.2981.4157.0683.2530.80
-------------------
0000000000000000000
-3-1-10-33-19-1-10-21-25-71-20212-78-95-45901945910
------5.00-76.92-140.00-125.00-788.89-1,683.335.83-46.99-50.26-22.6124.9334.2256.88-
-3-1-10-32-19-1-10-21-26-72-2039-29-83-5919135392506
--66.67900.00220.00-40.63-94.74900.00110.0023.81176.92181.94-104.43-422.22186.21-28.92-132.20610.53190.3729.08
1.11.11.523.123.110.112.120.326.327.126.63000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Arcturus Therapeutics Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Arcturus Therapeutics Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
0.60.150.121.750.78.348.636.771.4462.9370.5391.9292.01
000003.60.54.52.22.13.42.832.06
0000000000000
0000000000000
00.10.10.31.60.31.80.60.82.85.18.762.52
0.60.250.22252.312.250.941.874.4467.8379403.4386.59
0000.10.21.3127.58.611.34540.93
0.500019000.30.300.500
0000000000000
0000000000000
0000000000000
000.10.10.10.10.10.10.10.12.12.11.89
0.500.10.219.31.41.12.47.98.713.947.142.81
1.10.250.322.271.613.65244.282.3476.5392.9450.5429.4
                         
00001000200200000027
7.67.667.471.5140.313.856.758.397.4540.3575.7608.4646.35
-6.6-8.2-18.7-51.6-71-12.2-23.1-44.9-71.7-143.8-347.5-338.1-367.87
0000000000000
0000000000000
1-0.648.719.969.41.633.813.625.7396.5228.2270.3278.51
0.1000.30.13.41.82.45.810.810.17.45.28
0.10.11.522.20.41.83.94.419.423.530.231.88
000.10.10.14.97.46.311.118.143.528.644.83
07000001000000000
0000000001.322.560.70
0.20.81.62.42.48.81112.621.349.699.6126.981.99
00000009.91513.840.600
0000000000000
000003.47.28.12016.524.453.168.9
000003.47.2183530.36553.168.9
0.20.81.62.42.412.218.230.656.379.9164.6180150.89
1.20.250.322.371.813.85244.282476.4392.8450.3429.4
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Arcturus Therapeutics Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Arcturus Therapeutics Holdings's financial health and stability.

Assets

Arcturus Therapeutics Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Arcturus Therapeutics Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Arcturus Therapeutics Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Arcturus Therapeutics Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-3-1-10-32-19-1-10-21-25-72-2039-29
0000000000112
0000000000000
0010-1-27-1152131-127
30382142413656435
0000000000002
0000000000000
-2-1-7-28-18-20-20-6-42-13531-18
0000000-10-1-3-7-2
-11-288-33010220-1-3-7-2
-11-288-330102300000
0000000000000
000000594046-5-27
205706601036436123
205706607104143648-2-24
-------------
0000000000000
0022-1914-3161134391-9021-45
-2.38-1.58-7.39-28.41-18.33-3.55-0.71-22.24-7.27-44.6-138.4524.26-21
0000000000000

Arcturus Therapeutics Holdings stock margins

The Arcturus Therapeutics Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Arcturus Therapeutics Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Arcturus Therapeutics Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Arcturus Therapeutics Holdings's sales revenue. A higher gross margin percentage indicates that the Arcturus Therapeutics Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Arcturus Therapeutics Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Arcturus Therapeutics Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Arcturus Therapeutics Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Arcturus Therapeutics Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Arcturus Therapeutics Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Arcturus Therapeutics Holdings Margin History

Arcturus Therapeutics Holdings Gross marginArcturus Therapeutics Holdings Profit marginArcturus Therapeutics Holdings EBIT marginArcturus Therapeutics Holdings Profit margin
2029e0 %0 %37.29 %
2028e0 %56.94 %37.79 %
2027e0 %34.21 %23.85 %
2026e0 %25 %5.46 %
2025e0 %-23.04 %-30.01 %
2024e0 %-50.39 %-44.13 %
20230 %-46.89 %-17.82 %
20220 %5.92 %4.51 %
20210 %-1,636.29 %-1,642.74 %
20200 %-752.63 %-758.95 %
20190 %-122.6 %-125 %
20180 %-137.97 %-137.97 %
20170 %-80.77 %-83.85 %
20160 %-4.9 %-7.84 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %

Arcturus Therapeutics Holdings Stock Sales Revenue, EBIT, Earnings per Share

The Arcturus Therapeutics Holdings earnings per share therefore indicates how much revenue Arcturus Therapeutics Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Arcturus Therapeutics Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Arcturus Therapeutics Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Arcturus Therapeutics Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Arcturus Therapeutics Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Arcturus Therapeutics Holdings Revenue, EBIT and net profit per share

DateArcturus Therapeutics Holdings Sales per ShareArcturus Therapeutics Holdings EBIT per shareArcturus Therapeutics Holdings Earnings per Share
2029e50.26 undefined0 undefined18.74 undefined
2028e38.42 undefined0 undefined14.52 undefined
2027e21 undefined0 undefined5.01 undefined
2026e13.38 undefined0 undefined0.73 undefined
2025e7.36 undefined0 undefined-2.21 undefined
2024e7 undefined0 undefined-3.09 undefined
20236.26 undefined-2.94 undefined-1.12 undefined
20227.6 undefined0.45 undefined0.34 undefined
20210.47 undefined-7.71 undefined-7.75 undefined
20200.47 undefined-3.52 undefined-3.55 undefined
20191.72 undefined-2.11 undefined-2.15 undefined
20181.56 undefined-2.16 undefined-2.16 undefined
20174.19 undefined-3.39 undefined-3.52 undefined
201610.2 undefined-0.5 undefined-0.8 undefined
20150 undefined-6.35 undefined-6.26 undefined
20140 undefined-16.55 undefined-16.4 undefined
20130 undefined-6.87 undefined-7 undefined
20120 undefined-1.36 undefined-1.45 undefined
20110 undefined-3.55 undefined-3.55 undefined

Arcturus Therapeutics Holdings business model

Arcturus Therapeutics is a biopharmaceutical company based in San Diego, California, founded in 2013. The company specializes in the development of RNA-based therapeutics and has developed a proprietary technology platform called "LUNAR" that enables safe and effective transport of RNA molecules into target cells. The technology, resulting from over a decade of research and development, allows for the development of drugs for a variety of diseases. Arcturus's business model focuses on forming partnerships with other pharmaceutical companies to accelerate the development of RNA-based therapeutics. The company collaborates with partners from various industries, ranging from large biotech companies to small startups, in order to promote the development of effective treatments. Arcturus also has its own pipeline of therapeutics in development. The company has formed partnerships with Janssen Pharmaceuticals, Takeda Pharmaceutical, Ultragenyx Pharmaceutical, and CureVac. Arcturus's pipeline includes a variety of therapeutics targeting different therapy areas, including oncology, critical care, and rare diseases. A key focus is on the treatment of liver diseases such as hemophilia B, alpha-1 antitrypsin deficiency, and factor VIII deficiency. Arcturus is also working on therapies for rare diseases like lysosomal storage disease and other diseases such as diabetes, kidney disease, and AIDS. One important product from Arcturus is the hepatitis B vaccine candidate, developed in partnership with Janssen Pharmaceuticals. The vaccine candidate utilizes Arcturus's LUNAR technology to generate an effective immune response against hepatitis B. Phase 2 studies of the vaccine have shown promising results, suggesting that the vaccine can play a significant role in combating hepatitis B. Another important product from Arcturus is ARO-AAT, developed for the treatment of alpha-1 antitrypsin deficiency. Deficiency of this protein can lead to liver and lung diseases, and currently there is no effective treatment method. ARO-AAT utilizes Arcturus's LUNAR technology to effectively transport RNA molecules to the affected cells. Clinical studies of ARO-AAT have been positively evaluated thus far. Arcturus also has plans to apply its RNA technology in the field of vaccine development, aiming to quickly and effectively respond to future pandemics and threats of infectious diseases. In summary, Arcturus Therapeutics is a biopharmaceutical company that has developed a proprietary RNA technology platform called LUNAR to develop safe and effective therapeutics for a variety of diseases. The company collaborates with a variety of partners to accelerate the development of RNA-based therapeutics. Arcturus has its own pipeline of therapeutics in development, including a hepatitis B vaccine candidate and ARO-AAT for the treatment of alpha-1 antitrypsin deficiency. The company also has plans to utilize its RNA technology for vaccine development to quickly and effectively respond to future infectious diseases. Arcturus Therapeutics Holdings is one of the most popular companies on Eulerpool.com.

Arcturus Therapeutics Holdings SWOT Analysis

Strengths

Arcturus Therapeutics Holdings Inc has several strengths that contribute to its success in the biotech industry:

  • Strong R&D capabilities and innovative approach to developing RNA-based therapeutics
  • Diverse pipeline of potential drugs, providing growth opportunities
  • Strategic partnerships with leading pharmaceutical companies, enhancing market reach
  • Experienced management team with expertise in pharmaceutical development and commercialization

Weaknesses

Despite its strengths, Arcturus Therapeutics Holdings Inc also faces certain weaknesses that can be addressed for improvement:

  • Reliance on external partnerships for product development and commercialization
  • Limited product portfolio compared to some competitors
  • Dependence on regulatory approvals for drug commercialization

Opportunities

Arcturus Therapeutics Holdings Inc can leverage the following opportunities to expand its market presence and revenue:

  • Increasing demand and acceptance of RNA-based therapeutics in the healthcare industry
  • Advancements in technology and knowledge of RNA-based drug delivery systems
  • Global expansion and entry into new markets
  • Potential partnerships with research institutions and universities for scientific advancements

Threats

Arcturus Therapeutics Holdings Inc faces certain threats that may pose challenges to its growth and profitability:

  • Intense competition from other biotech companies in the field of RNA-based therapeutics
  • Regulatory and legal challenges related to drug approval processes
  • Potential negative public perception and skepticism regarding RNA-based therapies
  • Economic and market uncertainties impacting healthcare investments and funding

Arcturus Therapeutics Holdings Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Arcturus Therapeutics Holdings Revenue by Segment

Segmente2022
Collaboration Revenue205.76 M USD
Grant Revenue244,000 USD

Arcturus Therapeutics Holdings Revenue by Region

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Arcturus Therapeutics Holdings Revenue by Segment

DateForeign countries
2022192.7 M USD
20215 M USD
20201 M USD
20197 M USD

Arcturus Therapeutics Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Arcturus Therapeutics Holdings historical P/E ratio, EBIT, and P/S ratio.

Arcturus Therapeutics Holdings shares outstanding

The number of shares was Arcturus Therapeutics Holdings in 2023 — This indicates how many shares 26.628 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Arcturus Therapeutics Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Arcturus Therapeutics Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Arcturus Therapeutics Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Arcturus Therapeutics Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Arcturus Therapeutics Holdings Stock splits

In Arcturus Therapeutics Holdings's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Arcturus Therapeutics Holdings.

Arcturus Therapeutics Holdings latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.63 -0.64  (60.74 %)2024 Q2
3/31/2024-1.21 -1  (17.53 %)2024 Q1
12/31/2023-1.01 -0.32  (68.38 %)2023 Q4
9/30/2023-1.73 -0.61  (64.65 %)2023 Q3
6/30/2023-0.22 -1.98  (-820.93 %)2023 Q2
3/31/20230.06 1.87  (2,970.61 %)2023 Q1
12/31/20221 4.43  (343.8 %)2022 Q4
9/30/2022-1.85 -1.33  (28.13 %)2022 Q3
6/30/2022-1.94 -0.82  (57.69 %)2022 Q2
3/31/2022-1.47 -1.94  (-32.29 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Arcturus Therapeutics Holdings stock

Eulerpool World ESG Rating (EESG©)

36/ 100

🌱 Environment

38

👫 Social

43

🏛️ Governance

27

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Arcturus Therapeutics Holdings list of shareholders

%
Name
Stocks
Change
Date
7.13800 % BlackRock Institutional Trust Company, N.A.1,930,116192,21812/31/2023
6.24870 % ARK Investment Management LLC1,689,649-358,0383/31/2024
6.02687 % State Street Global Advisors (US)1,629,666-38,25912/31/2023
5.47373 % Payne (Joseph E)1,480,09704/15/2023
5.37392 % The Vanguard Group, Inc.1,453,10751,53712/31/2023
4.72085 % Nikko Asset Management Co., Ltd.1,276,519-44,1333/31/2024
4.02711 % Dimensional Fund Advisors, L.P.1,088,930115,08712/31/2023
3.95641 % Woodline Partners LP1,069,814012/31/2023
3.19659 % Fidelity Management & Research Company LLC864,358-75,92312/31/2023
2.04954 % Morgan Stanley & Co. LLC554,1961,64712/31/2023
1
2
3
4
5
...
10

Arcturus Therapeutics Holdings Executives and Management Board

Mr. Joseph Payne51
Arcturus Therapeutics Holdings President, Chief Executive Officer, Director (since 2013)
Compensation 5.59 M
Mr. Andrew Sassine58
Arcturus Therapeutics Holdings Chief Financial Officer, Director (since 2018)
Compensation 3.15 M
Dr. Padmanabh Chivukula43
Arcturus Therapeutics Holdings Chief Operating Officer, Chief Scientific Officer
Compensation 3.11 M
Mr. Lance Kurata53
Arcturus Therapeutics Holdings Chief Legal Officer
Compensation 560,000
Dr. John Markels57
Arcturus Therapeutics Holdings Independent Director
Compensation 486,827
1
2

Arcturus Therapeutics Holdings Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Arbutus Biopharma Stock
Arbutus Biopharma
SupplierCustomer0,940,790,690,890,700,56
Catalent Stock
Catalent
SupplierCustomer0,930,250,710,900,900,02
Danaher Stock
Danaher
SupplierCustomer0,800,770,890,920,83-0,32
CureVac Stock
CureVac
SupplierCustomer0,620,390,680,890,78-
Takeda Pharmaceutical Stock
Takeda Pharmaceutical
SupplierCustomer0,470,17-0,19-0,77-0,020,18
Ultragenyx Pharmaceutical Stock
Ultragenyx Pharmaceutical
SupplierCustomer0,020,800,800,810,790,75
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer-0,53-0,45-0,20-0,60-0,25-0,55
1

Most common questions regarding Arcturus Therapeutics Holdings

What values and corporate philosophy does Arcturus Therapeutics Holdings represent?

Arcturus Therapeutics Holdings Inc represents a commitment to revolutionizing the field of RNA medicines. The company focuses on developing breakthrough therapies to address unmet medical needs. Arcturus Therapeutics places a strong emphasis on creating value for patients, healthcare providers, and shareholders. With a patient-centric approach, the company aims to drive innovative advancements in the RNA therapeutic space. Arcturus Therapeutics also upholds a philosophy of collaboration and partnerships to accelerate the development and commercialization of transformative medicines. By combining scientific expertise and a forward-thinking mindset, the company strives to improve the lives of individuals worldwide through cutting-edge RNA-based therapies.

In which countries and regions is Arcturus Therapeutics Holdings primarily present?

Arcturus Therapeutics Holdings Inc primarily operates in the United States, focusing on the development and commercialization of RNA therapeutics.

What significant milestones has the company Arcturus Therapeutics Holdings achieved?

Arcturus Therapeutics Holdings Inc has achieved several significant milestones. Firstly, the company successfully developed and gained approval for its COVID-19 vaccine candidate, ARCT-021. Additionally, Arcturus Therapeutics entered into partnerships with global pharmaceutical companies to facilitate the production and distribution of their vaccine technology. The company also received funding from various organizations, including the Singapore Economic Development Board. Moreover, Arcturus Therapeutics expanded its pipeline by initiating clinical trials for therapies targeting various diseases, including rare liver diseases and viral hepatitis. These achievements demonstrate the company's dedication to advancing innovative therapeutics and its commitment to addressing unmet medical needs.

What is the history and background of the company Arcturus Therapeutics Holdings?

Arcturus Therapeutics Holdings Inc. is a renowned biotechnology company specializing in the development of RNA medicines. Founded in 2013, the company is headquartered in San Diego, California. Arcturus Therapeutics focuses on leveraging its proprietary technologies, including LUNAR® and STARR™, to develop innovative therapeutics for various diseases. With a strong emphasis on messenger RNA (mRNA) medicines, Arcturus aims to revolutionize the treatment landscape by providing safe and efficient therapies. Additionally, the company has strategic collaborations and partnerships with leading organizations to accelerate therapeutic advancements. Arcturus Therapeutics Holdings Inc. continues to strive towards advancing RNA medicines to address unmet medical needs globally.

Who are the main competitors of Arcturus Therapeutics Holdings in the market?

The main competitors of Arcturus Therapeutics Holdings Inc in the market are Moderna Inc, BioNTech SE, and Translate Bio Inc.

In which industries is Arcturus Therapeutics Holdings primarily active?

Arcturus Therapeutics Holdings Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Arcturus Therapeutics Holdings?

The business model of Arcturus Therapeutics Holdings Inc is focused on developing and commercializing RNA-based therapeutics. The company utilizes its proprietary LUNAR® lipid-mediated delivery system to enable efficient and targeted delivery of RNA medicines. Arcturus Therapeutics aims to address unmet medical needs through the development of novel RNA therapies for various diseases. The company leverages its expertise in RNA science and drug delivery technology to advance a robust pipeline of potential treatments. Arcturus Therapeutics partners with pharmaceutical companies and research organizations to accelerate the development and commercialization of its innovative therapies.

What is the P/E ratio of Arcturus Therapeutics Holdings 2024?

The Arcturus Therapeutics Holdings P/E ratio is -6.55.

What is the P/S ratio of Arcturus Therapeutics Holdings 2024?

The Arcturus Therapeutics Holdings P/S ratio is 2.89.

What is the AlleAktien quality score of Arcturus Therapeutics Holdings?

The AlleAktien quality score for Arcturus Therapeutics Holdings is 4/10.

What is the revenue of Arcturus Therapeutics Holdings 2024?

The expected Arcturus Therapeutics Holdings revenue is 189.25 M USD.

How high is the profit of Arcturus Therapeutics Holdings 2024?

The expected Arcturus Therapeutics Holdings profit is -83.51 M USD.

What is the business model of Arcturus Therapeutics Holdings

Arcturus Therapeutics is a biopharmaceutical company that focuses on RNA-based therapies and vaccines. The company's business model is centered around the development and commercialization of therapy products based on their proprietary technology platform. They offer a wide range of RNA-based therapies for severe and rare diseases that currently do not have satisfactory treatments. They also provide services to support the development of mRNA-based therapy products for biotechnology and pharmaceutical companies. Arcturus Therapeutics has developed a technology platform for the rapid and effective development of vaccines against infectious diseases using RNA technology. They collaborate with strategic partners such as Ultragenyx Pharmaceutical and Janssen Pharmaceuticals to optimize RNA technologies for therapy and vaccine production. Arcturus Therapeutics utilizes proprietary technology platforms including the STARR platform for gene silencing and the LUNAR platform for therapeutic use of mRNA. The company has gained significant attention and success in the field of RNA technology and has established a strong position in the market. With a strong pipeline of RNA-based therapies and vaccines, Arcturus will continue to play an important role in the biopharmaceutical industry.

What is the Arcturus Therapeutics Holdings dividend?

Arcturus Therapeutics Holdings pays a dividend of 0 USD distributed over payouts per year.

How often does Arcturus Therapeutics Holdings pay dividends?

The dividend cannot currently be calculated for Arcturus Therapeutics Holdings or the company does not pay out a dividend.

What is the Arcturus Therapeutics Holdings ISIN?

The ISIN of Arcturus Therapeutics Holdings is US03969T1097.

What is the Arcturus Therapeutics Holdings WKN?

The WKN of Arcturus Therapeutics Holdings is A2PMAS.

What is the Arcturus Therapeutics Holdings ticker?

The ticker of Arcturus Therapeutics Holdings is ARCT.

How much dividend does Arcturus Therapeutics Holdings pay?

Over the past 12 months, Arcturus Therapeutics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arcturus Therapeutics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Arcturus Therapeutics Holdings?

The current dividend yield of Arcturus Therapeutics Holdings is .

When does Arcturus Therapeutics Holdings pay dividends?

Arcturus Therapeutics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arcturus Therapeutics Holdings?

Arcturus Therapeutics Holdings paid dividends every year for the past 0 years.

What is the dividend of Arcturus Therapeutics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arcturus Therapeutics Holdings located?

Arcturus Therapeutics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arcturus Therapeutics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arcturus Therapeutics Holdings from 9/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.

When did Arcturus Therapeutics Holdings pay the last dividend?

The last dividend was paid out on 9/19/2024.

What was the dividend of Arcturus Therapeutics Holdings in the year 2023?

In the year 2023, Arcturus Therapeutics Holdings distributed 0 USD as dividends.

In which currency does Arcturus Therapeutics Holdings pay out the dividend?

The dividends of Arcturus Therapeutics Holdings are distributed in USD.

All fundamentals about Arcturus Therapeutics Holdings

Our stock analysis for Arcturus Therapeutics Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arcturus Therapeutics Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.